Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer.

IF 1.7 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2025-04-01 DOI:10.21873/anticanres.17551

Takaaki Fujii, Yuko Nakazawa, Mayu Aoki, Keiko Tanabe, Misato Ogino, Sayaka Obayashi, Ken Shirabe

{"title":"Cardioprotective Effect of Pegfilgrastim on Chemotherapy-induced Cardiotoxicity in Preoperative Chemotherapy for Breast Cancer.","authors":"Takaaki Fujii, Yuko Nakazawa, Mayu Aoki, Keiko Tanabe, Misato Ogino, Sayaka Obayashi, Ken Shirabe","doi":"10.21873/anticanres.17551","DOIUrl":null,"url":null,"abstract":"Background/aim: Chemotherapy for breast cancer, particularly with anthracyclines and trastuzumab, is known to induce cardiotoxicity. Pegfilgrastim, a granulocyte colony-stimulating factor analog used to prevent chemotherapy-induced neutropenia, has shown potential myocardial protective effects. This study investigated pegfilgrastim's effect on preoperative chemotherapy-induced cardiotoxicity.Patients and methods: We retrospectively reviewed 110 patients who underwent preoperative chemotherapy from 2010 to 2019 and whose cardiac function was evaluated before and after chemotherapy. All patients received either Adriamycin or Fluorouracil, Epirubicin, and Cyclophosphamide as anthracyclines; in HER2-positive breast cancer, taxanes were combined with anti-HER2 therapy. Cardiac function was evaluated by ultrasound before and after chemotherapy.Results: Sixty-one patients treated with pegfilgrastim were compared to 49 non-treated patients. Cardiac function did not change with chemotherapy in the pegfilgrastim group; however, the ejection fraction with chemotherapy in the non-pegfilgrastim group decreased significantly (p=0.027).Conclusion: Pegfilgrastim may reduce chemotherapy-induced cardiotoxicity in addition to preventing febrile neutropenia.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 4","pages":"1707-1712"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17551","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Chemotherapy for breast cancer, particularly with anthracyclines and trastuzumab, is known to induce cardiotoxicity. Pegfilgrastim, a granulocyte colony-stimulating factor analog used to prevent chemotherapy-induced neutropenia, has shown potential myocardial protective effects. This study investigated pegfilgrastim's effect on preoperative chemotherapy-induced cardiotoxicity.

Patients and methods: We retrospectively reviewed 110 patients who underwent preoperative chemotherapy from 2010 to 2019 and whose cardiac function was evaluated before and after chemotherapy. All patients received either Adriamycin or Fluorouracil, Epirubicin, and Cyclophosphamide as anthracyclines; in HER2-positive breast cancer, taxanes were combined with anti-HER2 therapy. Cardiac function was evaluated by ultrasound before and after chemotherapy.

Results: Sixty-one patients treated with pegfilgrastim were compared to 49 non-treated patients. Cardiac function did not change with chemotherapy in the pegfilgrastim group; however, the ejection fraction with chemotherapy in the non-pegfilgrastim group decreased significantly (p=0.027).

Conclusion: Pegfilgrastim may reduce chemotherapy-induced cardiotoxicity in addition to preventing febrile neutropenia.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Pegfilgrastim对乳腺癌术前化疗引起的心脏毒性的保护作用

背景/目的：乳腺癌化疗，特别是蒽环类药物和曲妥珠单抗，已知会诱导心脏毒性。Pegfilgrastim是一种粒细胞集落刺激因子类似物，用于预防化疗诱导的中性粒细胞减少症，已显示出潜在的心肌保护作用。本研究探讨了聚非格拉司汀对术前化疗引起的心脏毒性的影响。患者和方法：我们回顾性分析了2010年至2019年110例术前化疗患者，并对其化疗前后的心功能进行了评估。所有患者均接受阿霉素或氟尿嘧啶、表柔比星和环磷酰胺作为蒽环类药物治疗；在her2阳性乳腺癌中，紫杉烷类药物联合抗her2治疗。化疗前后采用超声检查心功能。结果：与49名未接受pegfilgrastim治疗的患者相比，接受pegfilgrastim治疗的患者有61名。聚非格昔汀组心功能未因化疗而改变；而非聚非格昔汀组化疗后射血分数明显降低（p=0.027）。结论：聚非格昔汀除可预防发热性中性粒细胞减少外，还可减轻化疗引起的心脏毒性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.